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The  efﬁcacy  of  eprinomectin  in  an  extended-release  injection  (ERI)  formulation  was  eval-
uated in  cattle  harbouring  induced  infestations  of Sarcoptes  scabiei  var.  bovis  (sarcoptic
mange)  in  three  studies  conducted  in Germany  (two  studies)  and  Austria  (one  study).  A
total of 44 cattle  were  included  in  the  studies,  12  in  one  study  and  16 in  each  of the  other
two  studies.  Approximately  eight  weeks  following  initial  induced  infestation,  cattle  in  each
study were  formed  into  replicates  of  two  animals  each  on  the basis  of  pre-treatment  body-
weights. Within  replicates  the  animals  were  randomly  allocated  to  one  of two  treatments:
ERI  vehicle  (control)  or Eprinomectin  5% (w/v)  ERI  (1.0 mg eprinomectin/kg).  Treatments
were  administered  at 1 mL/50  kg bodyweight  by subcutaneous  injection  in  front  of  the
shoulder  once  on  day  0.  The number  of live  mites  in skin  scrapings  was  determined  prior  to
treatment and at  weekly  intervals  for eight  weeks  after  treatment.  Severity  of skin  lesions
was  evaluated  and  scored  when  skin  scrapings  were  taken.  In all  studies,  animals  were
weighed  before  infestation  and  again  prior  to  and  at 56  days  after  treatment.
Mite  counts  for  treated  cattle  were  signiﬁcantly  (p  < 0.05)  lower  than  counts  for controls
from Day  7  onwards.  Cattle  treated  with  Eprinomectin  ERI  were  Sarcoptes  mite-free  from
seven, 21  or  28  days  post-treatment  to  the  end  of the study  in  the three  studies,  and  lesions
regressed  accordingly.  Mean  weight  gain  over  the  post-treatment  period  was  signiﬁcantly
higher  for  treated  cattle  than  for controls  in  two  studies.  All  animals  accepted  the treatment
well.
 . Introduction
Sarcoptic mange is caused by infestation with mites of
he  species Sarcoptes scabiei. Based on adaptation to sev-
ral  host species, varieties have been accepted and the mite
nfesting  cattle is named S. scabiei var. bovis (syn. S. bovis).
Sarcoptes mites burrow into the epidermis creating
unnels of up to 1 cm in length, in which they feed
nd reproduce. Their burrowing and feeding activities
ause inﬂammation and severe pruritus, loss of hair, and
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excoriation, marked thickening, and proliferation of the
epidermal layer of the skin.
Sarcoptic mange is highly contagious and transferred by
close  physical contact between animals. It tends to spread
all  over the body of cattle and may  result in considerable
economic losses. The intense irritation and the alteration
of  the normal skin morphology and function lead to poor
weight  gain and lower feed conversion efﬁcacy, impairing
the  value of the carcass, and they cause severe defects of the
hide  which result in substantial devaluation of the leather.
Open access under CC BY-NC-ND license.In  addition, sarcoptic mange causes disturbances in normal
behaviour with increasing levels of rubbing and scratching
and  a reduction in time spent lying down (Rehbein et al.,
2003a,  2003b).
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Eprinomectin belongs to the avermectin subclass of the
macrocyclic lactone parasiticides (Shoop and Soll, 2002). It
has demonstrated excellent nematocidal, insecticidal and
miticidal activity against a wide range of internal and exter-
nal parasites of cattle (Shoop et al., 1996; Gogolewski et al.,
1997a, 1997b; Holste et al., 1997, 1998; Pitt et al., 1997;
Williams et al., 1997; Yazwinski et al., 1997; Campbell
et al., 2001; Rehbein et al., 2005). Activity of eprinomectin
in a 0.5% formulation administered topically at 1 mL/10 kg
bodyweight (0.5 mg  eprinomectin/kg) against Sarcoptes
mite infestations was reported in several controlled studies
and under ﬁeld conditions (Barth et al., 1997; Thompson
et al., 1997; Watson and Forbes, 2000; Rehbein et al.,
2003a).
In order to extend the persistent activity of epri-
nomectin with regard to endoparasites, an injectable
formulation has been developed which releases the active
in concentrations to provide effective control of nema-
tode infections in cattle for up to 150 days (Soll et al.,
2013). In this extended-release injection (ERI) formula-
tion, eprinomectin is released from a matrix formed with
poly(d,l-lactide-co-glycolic)acid (PLGA). PLGA is known as
a safe and effective biodegradable material which has been
used as a drug delivery system for extended release appli-
cations of various pharmaceutical compounds, including
ivermectin (Lewis, 1990; Miller et al., 1999; Clark et al.,
2004; Winzenburg et al., 2004).
The objective of the studies reported here was  to
evaluate the therapeutic efﬁcacy of Eprinomectin ERI for-
mulation against infestations with S. scabiei var. bovis
(sarcoptic mange) on cattle.
2. Materials and methods
A total of three controlled studies were conducted
according to similar protocols, two in Germany and one in
Austria. The studies were designed and conducted to com-
ply with the regulatory requirements of both the FDA/CVM
and the European Medicines Agency/Committee for Medic-
inal Products for Veterinary Use, and according to relevant
guidelines for Good Clinical Practices (GCPs) and for estab-
lishing the efﬁcacy of acaricides against mange mites on
ruminants (Vercruysse et al., 2006).
The studies were performed as blinded studies, i.e., all
personnel involved in collecting data were masked to the
treatment assignment of the animals.
2.1. Experimental animals
A total of 44 (28 male and 16 female) healthy, rumi-
nating Braunvieh (Brown Swiss) or Fleckvieh (Simmental)
cattle, weighing 149–248 kg prior to treatment (day-1), and
aged approximately ﬁve to seven months, were included in
three studies conducted in Germany (studies 1 and 2) and
in Austria (study 3). The animal descriptions and details are
presented in Table 1. Animals had not been treated previ-
ously with an avermectin or milbemycin product and were
free of Sarcoptes mite infestation (as determined by thor-
ough body inspection and/or examination of skin scrapings
prior to initial mite infestation).logy 192 (2013) 359– 364
In all studies, cattle were held indoors under con-
ventional conditions including ambient temperature and
lighting. They were individually housed, tethered and
stanchioned so as to prevent self-grooming and physical
contact between animals. The animals were maintained
on forage-based diets in each of the studies as per local
practice (hay combined with either corn cobs or corn
silage). Drinking water was supplied by automatic water-
ers.
Animals were handled and treated with due regard for
their welfare and in compliance with Merial Institutional
Animal Care and Use Committee (IACUC) approvals, as well
as according to applicable local regulations, and require-
ments of the local IACUC.
2.2. Infestations
In each study, the animals were infested experimentally
at the withers with the following numbers of S. scabiei var.
bovis mites: study 1, ∼7300 and ∼6400 mites applied on
study days −56 and −49, respectively; study 2, ∼6800 and
∼4200 mites applied on study days −56 and −50, respec-
tively; study 3, ∼1600 and ∼2800 mites applied on study
days −57 and −48, respectively. The Sarcoptes strain used
for experimental infestation of cattle in the German stud-
ies was  isolated from a naturally-infested cow in Germany
and had been passaged continuously on cattle before being
used for infestation of the study animals. The Sarcoptes
mites used to infest the cattle in the Austrian study were
collected directly from a naturally-infested Braunvieh cow
purchased at a local livestock market in Austria shortly
before the commencement of the study in late autumn.
2.3. Experimental design
A randomized block design based on pre-treatment
bodyweight was  used in each study with the individual
animal being the experimental unit. Six (study 1) or eight
replicates of two cattle each (studies 2 and 3) were formed
sequentially based on decreasing pre-treatment (day −1)
bodyweight. Within replicates, animals were allocated ran-
domly to treatment: one to the control (vehicle-treated)
group and one to the Eprinomectin ERI group. Six or eight
blocks of stanchions were formed. Assignments of repli-
cates to blocks and of animals within blocks to stanchion
were done at random.
Treatments, vehicle (formulation that consisted of
the excipients of the Eprinomectin ERI) or Eprinomectin
ERI (eprinomectin 5% in a PLGA-based formulation) at
1.0 mg  eprinomectin/kg, were administered at 1 mL/50 kg
(1 mL/110 lb) bodyweight once (day 0) by subcutaneous
injection in front of the shoulder using commercial dispos-
able syringes and needles. All cattle were observed hourly
for four or ﬁve hours post-treatment and thereafter once
daily throughout the studies for health problems or adverse
drug events.Animals were weighed prior to initial infestation (day
−56 for studies 1 and 2, day −58 for study 3), prior to treat-
ment (day −1) for allocation and dose calculation, and at
study end (day 56).
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Table  1
Animal description and details.
Study Treatmenta/Animals per TREATMENT Breed Sex ∼Age (months) Pre-treatment bodyweight (kg)
1 Control, n = 6 Braunvieh Male 6.5 149–174
EpERI,  n = 6 (Brown Swiss)
2 Control, n = 8 Fleckvieh Male 7  210–248
EpERI, n = 8 (Simmental)
l)
2
t
i
b
m
3
o
m
t
t
w
s
T
E
n3 Control, n = 8 Fleckvieh
EpERI, n = 8 (Simmenta
a Control = ERI vehicle-treated; EpERI = Eprinomectin ERI.
.4. Mite counts and mange lesion scores
Live mites were counted in scrapings collected from
he edges of active lesions or, if lesions regressed dur-
ng the study, from the area where active lesions had
een present at study commencement. Scrapings were
ade using a sharp spoon from an area approximately
 cm ×3 cm.  Six sites were scraped on each animal at each
ccasion. Scrapings were taken on day −1 prior to treat-
ent, on day 7, and at approximately 7-day intervalshereafter until study termination on day 56. For counting
he mites, warm water with a small amount of detergent
as added to each scraping sample, and the sample was
haken for 10 min. Then the mites were washed out of the
able 2
volution of Sarcoptes scabiei var. bovis mite counts in experimentally infested 
omectin ERI on Study Day 0 and followed-up for eight weeks after treatment.
Study Study day Control (ERI vehicle) E
Preva GMb,c (range) P
Live Sarcoptes scabiei var. bovis mites
1 −1 6/6 >276.2 (68 –>600) 6
7 6/6 >303.9 (28 –>600) 2
14  6/6 >385.1 (71–>600) 1
21  6/6 >336.9 (37–>600) 0
28  6/6 >341.3 (23–>600) 0
36 6/6 >323.7 (22–>600) 0
42  6/6 >254.9 (5–>600) 0
49  6/6 >255.1 (5–>600) 0
56  6/6 >204.8 (2–>600) 0
2 −1  8/8 >311.0 (71–>600) 8
7  8/8 >398.0 (75–>600) 0
14  8/8 >421.3 (136–>600) 0
21  8/8 >487.3 (158–>600) 0
28  8/8 >519.1 (>402–>600) 0
35 8/8 >547.4 (>368–>600) 0
42  8/8 >563.7 (>483–>600) 0
49  8/8 >545.2 (>401–>600) 0
56  8/8 >562.8 (>436–>600) 0
3 −1  8/8 64.6 (15–1232) 8
7  8/8 120.3 (35–1620) 5
14 8/8  124.3 (45–545) 1
21  8/8 177.7 (15–11331) 1
28  8/8 151.6 (10–2488) 0
35  8/8 218.0 (11–2275) 0
42  8/8 187.6 (6–1863) 0
49 8/8 254.6 (2–4804) 0
56  8/8 501.5 (5–1508) 0
a Prevalence: number of cattle infested/Number of cattle in group.
b Geometric mean counts (based on transformation to the natural logarithm of
c Mean preceded by “>” had at least one animal with a site with more than 100
d Efﬁcacy = 100 × (GM control [ERI vehicle] − GM Eprinomectin ERI/GM control
e Probability from Wilcoxon rank sum test.
f Not signiﬁcant at  ˛ = 0.05.Female 5–7 150–221
samples onto black ﬁlter paper by ﬁltering the material
through a Buchner funnel apparatus equipped with a vac-
uum pump. The black ﬁlter paper discs were thoroughly
examined for living mites (assessed based on motility)
using a stereoscopic microscope (Barth and Visser, 1985).
The live mites present in each scraping were counted up
to a maximum of 100 in studies 1 and 2; counts above
100 were recorded as “>100”. In study 3, all live mites
present in a scraping were counted. Total mite counts at
each time point were calculated from summing the counts
from each scraping site for each animal. The site of each
scraping was recorded on a silhouette in addition to the
assessment (score) of the mange lesions at each examina-
tion.
cattle which were either vehicle-treated (control) or treated with Epri-
prinomectin ERI Efﬁcacyd Probabilitye
rev GM (range)
/6 >235.5 (110–508) – nsf
/6 0.6 (0–5) >99% <0.05
/6 0.1 (0–1) >99% <0.05
/6 0 100% <0.05
/6 0 100% <0.05
/6 0 100% <0.05
/6 0 100% <0.05
/6 0 100% <0.05
/6 0 100% <0.05
/8 >281.4 (73–>600) – ns
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 69.9 (17–425) – ns
/8 2.9 (0–240) 97.6% <0.05
/8 0.6 (0–39) >99% <0.05
/8 0.2 (0–4) >99% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
/8 0 100% <0.05
 [count + 1]).
 mites.
 [ERI vehicle]).
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Table 3
Evolution of mange lesion scores in experimentally infested cattle which were either vehicle-treated (control) or treated with Eprinomectin ERI on Study
Day  0 and followed-up for eight weeks after treatment.
Study Study day Mange lesion scorea (number of animals) Probabilityb
Control (ERI vehicle) Eprinomectin ERI
(n  = 6 or 8) (n = 6 or 8)
1 −1 ++ (6) ++ (6) nsc
7 ++ (6) ++ (6) ns
14 ++ (4)/+++ (2) (+) (5)/++ (1) <0.05
21 ++ (3)/+++ (3) (+) (6) <0.05
28  ++ (2)/+++ (4) (+) (6) <0.05
36 ++ (2)/+++ (4) (+) (6) <0.05
42  ++ (2)/+++ (4) (+) (6) <0.05
49  ++ (2)/+++ (4) (+) (6) <0.05
56  ++ (1)/+++ (5) (+) (6) <0.05
2 −1  ++ (8) ++ (8) ns
7  ++ (7)/+++ (1) ++ (8) ns
14  ++ (6)/+++ (2) (+) (1)/++ (7) ns
21 ++ (6)/+++ (2) (+) (8) <0.05
28  ++ (6)/+++ (2) (+) (8) <0.05
35 ++ (4)/+++ (4) (+) (8) <0.05
42  ++ (5)/+++ (3) (+) (8) <0.05
49  ++ (5)/+++ (3) 0 (2)/(+) (6) <0.05
56 ++ (1)/+++ (7) 0 (7)/(+) (1) <0.05
3 −1  ++ (8) ++ (8) ns
7  ++ (8) ++ (8) ns
14 ++ (8) + (3)/++ (5) ns
21  ++ (8) 0 (2)/(+) (4)/+ (2) <0.05
28  ++ (8) 0 (5)/(+) (1)/+ (2) <0.05
35 ++ (8) 0 (6)/(+) (2) <0.05
42  + (1)/++ (7) 0 (6)/(+) (2) <0.05
49 +  (1)/++ (7) 0 (6)/(+) (2) <0.05
56  + (1)/++ (7) 0 (7)/(+) (1) <0.05
 but hai
ve lesio
I to cona 0 = healthy skin. (+) = healing lesion, crusts lifted and detached easily
hand.  ++ = active lesion, extent more than the palm of the hand. +++ = acti
b Probability from Wilcoxon rank sum test comparing Eprinomectin ER
c Not signiﬁcant at  ˛ = 0.05.
When skin scrapings were taken, the mange lesions
were assessed and scored as follows (Rehbein et al., 2003b):
0 = healthy skin; (+) = healing lesion, crusts detached
easily but hair growth not complete; + = active lesion,
extent of less than the palm of the hand; ++ = active lesion,
extent of more than the palm of the hand; +++ = active
lesion, extent of more than half of the body of the animal.
2.5. Statistical methods
The number of living mites at each time point was
transformed to the natural logarithm of (count + 1) for
calculation of geometric means. Treatment groups were
compared using Wilcoxon rank sum test at each time point.
A two-sided test was used at the 0.05 signiﬁcance level.
Efﬁcacy was calculated as 100[(C − T)/C], where C is the geo-
metric mean for the control (ERI vehicle-treated) group and
T is the geometric mean for the Eprinomectin ERI-treated
group. Bodyweight and weight gain were analyzed using a
mixed model analysis of variance including treatment as a
ﬁxed effect and replicate as a random effect. Lesion scores
were analyzed using Wilcoxon rank sum test at each time
point.3. Results
Following infestation, all 44 experimental animals
developed active mange lesions spreading from ther growth not complete. + = active lesion, extent less than the palm of the
n, extent more than half of the body of the animal.
trol (ERI vehicle).
withers mainly over the shoulder to the chest, the ﬂanks
and the back as conﬁrmed by pre-treatment examination.
All 22 control (vehicle-treated) animals remained infested
with S. scabiei var. bovis, and active lesions were recorded
on all of them, throughout the duration of the studies
(Tables 2 and 3). Mange lesions covering more than half
of the body surface were observed in 5 and 7 control
animals in studies 1 and 2, respectively. Therefore, those
animals received salvage treatments (topical organophos-
phate spray) for welfare reasons to prevent further spread
of mange. After end of the studies, all control animals were
appropriately treated with an authorized acaricidal prod-
uct.
Live mite counts of the Eprinomectin ERI-treated cat-
tle were signiﬁcantly (p < 0.05) lower than the control
(vehicle-treated) cattle counts at all post-treatment study
days. Reductions of mite counts were 100% from days 21,
7, and 28 for studies 1, 2, and 3, respectively. Mite counts
are summarized in Table 2.
Mange lesion scores of Eprinomectin ERI-treated cat-
tle at study days 14–56 (study 1), and days 21–56 (studies
2 and 3), were signiﬁcantly (p < 0.05) lower than the con-
trol (vehicle-treated) cattle scores. No “active” lesions were
observed on any treated animal from ﬁve weeks after treat-
ment onwards to the end of the studies whereas all control
(vehicle-treated) cattle had active lesions throughout the
study (Table 3).
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Bodyweight and weight gain data are summarized in
able 4. There was no difference in the weight gain of
he animals of the two treatment groups during the pre-
reatment period (day −58/−56 to day −1). During the
ight week observation period following day 0 treatment,
attle treated with Eprinomectin ERI gained more weight
han the ERI vehicle-treated controls in all three studies
24.1 kg, 14.2 kg and 4.1 kg, respectively). The difference in
nal weight and bodyweight gain was signiﬁcantly differ-
nt from controls (p < 0.05) in two studies, but not in the
hird.
With the exception of signs associated with mange
nfestation, all animals were reported as normal. Hourly
bservations for four or ﬁve hours post-treatment, revealed
o changes from pre-treatment health status, indicating
hat Eprinomectin ERI and ERI vehicle treatments were well
ccepted. There were no drug-related health problems or
dverse drug events observed at any time during the stud-
es.
. Discussion
In these studies, a single injection of Eprinomectin ERI
ffectively eliminated Sarcoptes mites from cattle, and the
apid reduction of mite counts was correlated to the clini-
al improvement in the treated animals. This efﬁcacy of the
prinomectin ERI against S. scabiei var. bovis was similar to
hat previously observed after pour-on application of the
.5% topical formulation of eprinomectin (Barth et al., 1997;
hompson et al., 1997; Watson and Forbes, 2000; Rehbein
t al., 2003a).  These results also are consistent with those
f other studies that evaluated the acaricidal activity of the
onventional 1% ivermectin and abamectin injectable for-
ulations (Barth and Sutherland, 1980, 1983; Lavigne and
mith, 1983; Dane˘k et al., 1985; Soll et al., 1987; Heinze-
utz et al., 1993; Rehbein et al., 2003b).
At study completion eight weeks following treatment,
here was still some evidence of skin damage at some
ites where active mange lesions were present before Epri-
omectin ERI treatment. This observation is most likely
elated to the limited ability of the study animals to groom.
n all of the treated animals, skin lesions were scored “heal-
ng” from ﬁve weeks following treatment.
Eprinomectin ERI treatment of cattle with sarcoptic
ange resulted in an improved weight gain compared to
he control animals, and this ﬁnding re-emphasizes the
egative impact of bovine sarcoptic mange on growth per-
ormance. This observation is in agreement with numerous
tudies where signiﬁcant improvements in weight gain
ave been reported for cattle which were infested with Sar-
optes mites and successfully treated with eprinomectin
our-on (Barth et al., 1997; Rehbein et al., 2003a),  iver-
ectin injection or pour-on (Dane˘k et al., 1985; Löwenstein
nd Kutzer, 1996; Rehbein et al., 2003b), or abamectin
njection (Heinze-Mutz et al., 1993). The higher weight gain
esponses observed with Eprinomectin ERI-treated cattle
n studies 1 and 2 compared to study 3 versus the respec-
ive controls are clearly related to the different levels of
nfestation as demonstrated by the results of examinations
f the vehicle-treated controls. Controls in studies 1 and 2
xhibited more severe infestations over the study period Ta
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than controls in study 3 based on average mite counts and
size of active mange lesions.
However, therapeutic intervention in sarcoptic mange
infested cattle is not only indicated for the clear impact on
productivity. Sarcoptic mange was demonstrated to have
animal welfare implications, and treatment resulted in
reduced levels of behaviors such as rubbing and scratching
and longer time spent lying down (Rehbein et al., 2003a).
In addition, there are reports of pruritic dermatoses in
humans who became infested with cattle sarcoptic mites
when handling infested animals (e.g., Mumcuoglu and
Ruﬂi, 1979; Haarløv and Møller-Madsen, 1983).
In conclusion, the results of the studies conﬁrmed the
excellent efﬁcacy of eprinomectin in an extended-release
formulation for treatment of bovine sarcoptic mange at
the dose that was selected to provide effective control of
nematode infections in cattle for up to 150 days.
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